Unknown

Dataset Information

0

Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.


ABSTRACT: Chronic phase-to-blast crisis transition in chronic myelogenous leukemia (CML) is associated with differentiation arrest and down-regulation of C/EBPalpha, a transcription factor essential for granulocyte differentiation. Patients with CML in blast crisis (CML-BC) became rapidly resistant to therapy with the breakpoint cluster region-Abelson murine leukemia (BCR/ABL) kinase inhibitor imatinib (STI571) because of mutations in the kinase domain that interfere with drug binding. We show here that the restoration of C/EBPalpha activity in STI571-sensitive or -resistant 32D-BCR/ABL cells induced granulocyte differentiation, inhibited proliferation in vitro and in mice, and suppressed leukemogenesis. Moreover, activation of C/EBPalpha eradicated leukemia in 4 of 10 and in 6 of 7 mice injected with STI571-sensitive or -resistant 32D-BCR/ABL cells, respectively. Differentiation induction and proliferation inhibition were required for optimal suppression of leukemogenesis, as indicated by the effects of p42 C/EBPalpha, which were more potent than those of K298E C/EBPalpha, a mutant defective in DNA binding and transcription activation that failed to induce granulocyte differentiation. Activation of C/EBPalpha in blast cells from 4 patients with CML-BC, including one resistant to STI571 and BMS-354825 and carrying the T315I Abl kinase domain mutation, also induced granulocyte differentiation. Thus, these data indicate that C/EBPalpha has potent antileukemia effects even in cells resistant to ATP-binding competitive tyrosine kinase inhibitors, and they portend the development of anti-leukemia therapies that rely on C/EBPalpha activation.

SUBMITTER: Ferrari-Amorotti G 

PROVIDER: S-EPMC1895881 | biostudies-literature | 2006 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.

Ferrari-Amorotti Giovanna G   Keeshan Karen K   Zattoni Michela M   Guerzoni Clara C   Iotti Giorgio G   Cattelani Sara S   Donato Nick J NJ   Calabretta Bruno B  

Blood 20060502 4


Chronic phase-to-blast crisis transition in chronic myelogenous leukemia (CML) is associated with differentiation arrest and down-regulation of C/EBPalpha, a transcription factor essential for granulocyte differentiation. Patients with CML in blast crisis (CML-BC) became rapidly resistant to therapy with the breakpoint cluster region-Abelson murine leukemia (BCR/ABL) kinase inhibitor imatinib (STI571) because of mutations in the kinase domain that interfere with drug binding. We show here that t  ...[more]

Similar Datasets

| S-EPMC1896118 | biostudies-literature
| S-EPMC3202669 | biostudies-literature
| S-EPMC2438443 | biostudies-literature
| S-EPMC3293644 | biostudies-literature
| S-EPMC3948164 | biostudies-literature
| S-EPMC2515380 | biostudies-literature
| S-EPMC3412345 | biostudies-literature
| S-EPMC4647898 | biostudies-other
| S-EPMC3081401 | biostudies-literature
| S-EPMC10125982 | biostudies-literature